Related Experiment Videos

MMP inhibition as a potential therapeutic strategy for CHF

M Lindsey1, R T Lee

  • 1Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

Drug News & Perspectives
|August 26, 2003
PubMed

Insights

Matrix metalloproteinase inhibition offers a novel therapy for congestive heart failure (CHF). Targeting these enzymes may prevent or delay heart failure by addressing ventricular dilation, a key factor in CHF progression.

Area of Science:

  • Cardiology
  • Biochemistry
  • Pathophysiology

Background:

  • Congestive heart failure (CHF) is a significant global health concern, with increasing prevalence worldwide.
  • Left ventricular dilation and impaired contractility are primary drivers of CHF.
  • Current therapies primarily target the neurohumoral system, with limited options addressing the dilation process itself.

Purpose of the Study:

  • To explore the role of matrix metalloproteinases (MMPs) in mediating ventricular dilation in CHF.
  • To investigate MMP inhibition as a potential therapeutic strategy for CHF.

Main Methods:

  • Analysis of emerging data on the association between MMPs and ventricular dilation.
  • Evaluation of MMPs as extracellular targets for pharmacologic intervention.

Main Results:

  • Emerging evidence suggests matrix metalloproteinases (MMPs) are associated with and may actively mediate ventricular dilation.
  • MMPs are extracellular enzymes and represent viable pharmacologic targets.

Conclusions:

  • Matrix metalloproteinase inhibition presents a novel therapeutic approach for managing congestive heart failure.
  • Targeting MMPs could offer a strategy to delay or prevent the progression of heart failure by mitigating ventricular dilation.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...